S. Jagannath

S. Jagannath, F. Cabanillas, J. Spinolo, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

High dose cyclophosphamide, BCNU, and VP‐16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia

S. Jagannath, A. Zander, M. Keating, 1987, Cancer.

High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma.

S. Jagannath, A. Zander, G. Spitzer, 1983, European journal of cancer & clinical oncology.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Population Pharmacokinetics and Exposure–Response Relationship of Carfilzomib in Patients With Multiple Myeloma

M. Dimopoulos, S. Jagannath, R. Vij, 2017, Journal of clinical pharmacology.

Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.

M. Buyse, S. Jagannath, R. Vij, 2015, Clinical lymphoma, myeloma & leukemia.

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2015, Leukemia & lymphoma.

Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

S. Jagannath, D. Siegel, R. Vij, 2010 .

Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

S. Jagannath, A. Jakubowiak, S. Lonial, 2009 .

Detection of leukemic cell colonies in agar plates by immunostaining for human malignancy-associated nucleolar antigen.

S. Jagannath, K. Dicke, P. Rao, 1983, Journal of immunological methods.

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

M. Caligiuri, C. Hofmeister, S. Jagannath, 2015, Clinical Cancer Research.

Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.

S. Jagannath, J. Hardwick, G. Schiller, 2012, Clinical lymphoma, myeloma & leukemia.

Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience

S. Jagannath, D. Siegel, V. Richon, 2008 .

Combination of Vorinostat Plus Bortezomib for the Treatment of Patients with Multiple Myeloma Who Have Previously Received Bortezomib

S. Jagannath, G. Schiller, R. Sobecks, 2008 .

Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.

S. Jagannath, J. Lutzky, B. Durie, 2006 .

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Blood.

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

M. Dimopoulos, S. Jagannath, P. Richardson, 2021, American journal of hematology.

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

M. Dimopoulos, S. Jagannath, P. Richardson, 2020, The Lancet.

A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM).

P. Sonneveld, S. Jagannath, P. Voorhees, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial

Linda Z Sun, H. Goldschmidt, M. Dimopoulos, 2011 .

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

A. Laganà, S. Jagannath, P. Poulikakos, 2022, Journal of Hematology & Oncology.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma

S. Jagannath, D. Madduri, S. Parekh, 2020, Expert review of hematology.

Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review

S. Jagannath, D. Madduri, S. Parekh, 2020, Expert review of hematology.

Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model

S. Jagannath, D. Siegel, D. Globe, 2016, Journal of managed care & specialty pharmacy.

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

S. Jagannath, D. Siegel, D. Globe, 2015, American health & drug benefits.

Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM).

S. Jagannath, A. Jakubowiak, D. Siegel, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

H. Goldschmidt, M. Dimopoulos, S. Jagannath, 2016, Clinical lymphoma, myeloma & leukemia.

Clinical application of Percoll gradient-separated bone marrow.

S. Jagannath, S. Tucker, G. Spitzer, 1987, Bone marrow transplantation.

High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma

S. Jagannath, G. Zagars, G. Spitzer, 1987 .

High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma.

B. Barlogie, S. Jagannath, G. Zagars, 1987, Blood.

Case report Lymphomatoid granulomatosis following autologous stem cell transplantation

B. Barlogie, S. Jagannath, N. Munshi, 1999 .

Lymphomatoid granulomatosis following autologous stem cell transplantation

B. Barlogie, S. Jagannath, N. Munshi, 1999, Bone Marrow Transplantation.

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

M. Dimopoulos, J. San Miguel, S. Jagannath, 2011, Blood.

Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.

S. Jagannath, A. Jakubowiak, P. Hari, 2022, Clinical lymphoma, myeloma & leukemia.

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

S. Jagannath, A. Jakubowiak, N. Munshi, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.

J. Hardin, S. Jagannath, S. Srinivasan, 2018, Blood advances.

Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

S. Jagannath, N. Munshi, M. Liedtke, 2019, The New England journal of medicine.

CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.

S. Jagannath, S. Devlin, A. Lesokhin, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

B. Barlogie, S. Jagannath, S. Singhal, 1998, Bone Marrow Transplantation.

Adverse drug reaction: pomalidomide-induced liver injury

S. Jagannath, S. Parekh, L. Isola, 2014, The Lancet.

Autologous bone marrow transplants: Different indications in Europe and North America

J. Armitage, A. Hagenbeek, N. Gale, 1989 .

Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma

S. Jagannath, D. Siegel, Chiung-Yu Huang, 2021, Cancer.

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

S. Jagannath, R. Vij, J. Kaufman, 2015, Clinical lymphoma, myeloma & leukemia.

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, S. Lonial, 2014 .

Two cases of plasma cell dyscrasias with systemic involvement of breast.

S. Jagannath, G. Morris, P. Schmidt, 2014, Seminars in oncology.

Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis.

S. Jagannath, A. Chari, K. Osman, 2013, Clinical lymphoma, myeloma & leukemia.

Transplants for multiple myeloma

B. Barlogie, S. Jagannath, G. Tricot, 1995 .

Autologous and allogeneic transplants for multiple myeloma.

B. Barlogie, S. Jagannath, G. Tricot, 1995, Seminars in hematology.

Autologous bone marrow transplantation for multiple myeloma.

B. Barlogie, S. Jagannath, 1992, Hematology/oncology clinics of North America.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, S. Lonial, 2012, Clinical lymphoma, myeloma & leukemia.

The role of autologous bone marrow transplantation in acute leukemia.

S. Jagannath, R. Walters, G. Spitzer, 1987, Annals of the New York Academy of Sciences.

Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience

B. Barlogie, S. Jagannath, D. Siegel, 2003, British journal of haematology.

Plasma exchange after hematopoietic stem cell transplantation in multiple myeloma to reduce renal insufficiency

S. Jagannath, D. Vesole, A. Mazumder, 2008, Bone Marrow Transplantation.

Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma.

S. Jagannath, H. Pri-Chen, A. Chari, 2013, Clinical lymphoma, myeloma & leukemia.

Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.

S. Jagannath, K. Ramasamy, R. Rifkin, 2022, Clinical lymphoma, myeloma & leukemia.

Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation

M. Dimopoulos, S. Jagannath, J. Spinolo, 1994, American journal of hematology.

Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study

Winnie S. Liang, J. Carpten, J. Fay, 2016 .

Management of treatment-emergent peripheral neuropathy in multiple myeloma

P. Wen, G. Morgan, M. Dimopoulos, 2012, Leukemia.

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

D. Esseltine, B. Barlogie, P. Wen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Infection – an underappreciated cause of bone pain in multiple myeloma

B. Barlogie, S. Jagannath, N. Munshi, 2003, British journal of haematology.

J. Dudley, A. Laganà, J. Keats, 2020, Science advances.

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.

S. Jagannath, A. Chanan-Khan, S. Ailawadhi, 2019, Clinical lymphoma, myeloma & leukemia.

The computational origin of representation and conceptual change

Steven Piantadosi, Sundar Jagannath, S. Piantadosi, 2016 .

Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

S. Jagannath, S. Tucker, W. Velasquez, 1988, Blood.

Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.

S. Jagannath, D. Madduri, S. Parekh, 2020, Clinical lymphoma, myeloma & leukemia.

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy

A. Laganà, S. Jagannath, J. Teruya-Feldstein, 2021, Nature Medicine.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

M. Dimopoulos, S. Jagannath, S. Lonial, 2019, The New England journal of medicine.

Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin.

B. Barlogie, S. Jagannath, G. Tricot, 1998, Blood.

Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation.

B. Barlogie, S. Jagannath, N. Munshi, 1998, Blood.

Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma

S. Jagannath, A. Palumbo, Emmanuelle Le Ray, 2016, Expert review of hematology.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Bin Li, Matthew Schu, R. Neuwirth, 2014, Blood.

Hematopoietic stem cell transplantation.

B. Barlogie, S. Jagannath, G. Tricot, 1993, Hospital practice.

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

J. Armitage, S. Jagannath, P. Biron, 1987, The New England journal of medicine.

Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.

B. Barlogie, S. Jagannath, G. Tricot, 1995, Blood.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

H. Goldschmidt, G. Morgan, A. Palumbo, 2012, Leukemia.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

H. Goldschmidt, G. Morgan, A. Palumbo, 2012, Leukemia.

Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma

J. Dudley, A. Laganà, S. Jagannath, 2019, Clinical Cancer Research.

Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma

S. Jagannath, T. Zimmerman, M. Oken, 2009, Leukemia & lymphoma.

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.

J. Armitage, S. Jagannath, S. Tucker, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of autologous bone marrow transplantation in various malignancies.

S. Jagannath, A. Zander, U. Jehn, 1984, Seminars in hematology.

Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy

J. Crowley, B. Barlogie, J. Shaughnessy, 2007, The Journal of experimental medicine.

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.

S. Jagannath, Hui-Yi Lin, D. Sullivan, 2016, Blood.

Phase II Study of Pomalidomide , Cyclophosphamide , and Dexamethasone in Relapsed Refractory Myeloma

S. Jagannath, Hui-Yi Lin, D. Sullivan, 2016 .

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, The Lancet. Oncology.

Graft-versus-myeloma effect: proof of principle.

B. Barlogie, S. Jagannath, N. Munshi, 1996, Blood.

Outcomes of salvage autologous stem cell transplantation for multiple myeloma with cytopenias and exposure to novel agents

S. Jagannath, E. Moshier, A. Chari, 2017, Bone Marrow Transplantation.

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

B. Barlogie, G. Morgan, M. Dimopoulos, 2009, Leukemia.

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

B. Barlogie, B. Cheson, S. Jagannath, 1997, Blood.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

H. Goldschmidt, U. Mellqvist, M. Dimopoulos, 2016, Leukemia.

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma

J. Dudley, B. Barlogie, D. Auclair, 2018, Leukemia.

Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.

S. Jagannath, E. Reddy, S. Parekh, 2016, Cancer research.

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Diane Warren, Edie Weller, S. Jagannath, 2006, Blood.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2004, British journal of haematology.

Enhancement of clonogenicity of human multiple myeloma by dendritic cells

S. Jagannath, M. Dhodapkar, D. Vesole, 2006, The Journal of experimental medicine.

Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2007, British journal of haematology.

A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission.

S. Jagannath, A. Zander, L. Peters, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bart Barlogie, Gordan Srkalovic, David Irwin, 2003, The New England journal of medicine.

Current & Emerging Therapeutics for Multiple Myeloma

S. Jagannath, N. Raje, 2013 .

Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2006, British journal of haematology.

High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants

J. Crowley, B. Barlogie, B. Cheson, 1994 .

An inflammatory cytokine signature helps predict COVID-19 severity and death

S. Jagannath, C. Cordon-Cardo, M. Merad, 2020, medRxiv.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

J. Friedberg, M. Shipp, P. L. Bergsagel, 2016, Journal of Immunotherapy for Cancer.

Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.

S. Jagannath, M. Dhodapkar, D. Vesole, 2007, Blood.

Autotransplants in multiple myeloma: what have we learned?

B. Barlogie, B. Cheson, S. Jagannath, 1996, Blood.

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Cancer.

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

M. Kaminski, K. Griffith, S. Jagannath, 2012, Blood.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010, Blood.

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

S. Jagannath, G. Gahrton, D. Reece, 1998, British journal of haematology.

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

A. Chinnaiyan, D. Auclair, P. L. Bergsagel, 2022, Nature Communications.

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

M Boccadoro, B. Barlogie, G. Morgan, 2009, Leukemia.

The Role of Autologous Bone Marrow Transplantation in Acute Leukemia a

S. Jagannath, R. Walters, G. Spitzer, 1987, Haematology and blood transfusion.

in the context of global gene expression survival in multiple myeloma treated with Total Therapy I: interpretation especially of chromosome 13 and hypodiploidy, ensures long-term Continuous absence of metaphase-defined cytogenetic abnormalities,

B. Barlogie, J. Shaughnessy, S. Jagannath, 2013 .

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.

F. Zhan, B. Barlogie, J. Shaughnessy, 2003, Blood.

Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.

B. Barlogie, J. Shaughnessy, S. Jagannath, 2000, Blood.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

B. Barlogie, B. Cheson, S. Jagannath, 1999, Blood.

High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.

B. Barlogie, B. Cheson, S. Jagannath, 1994, Blood.

Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.

S. Jagannath, F. Cabanillas, J. Spinolo, 1993, Leukemia & lymphoma.

Autotransplantation in multiple myeloma.

B. Barlogie, S. Jagannath, D. Vesole, 1993, Hematology/oncology clinics of North America.

Hematopoietic stem cell transplants for multiple myeloma.

B. Barlogie, S. Jagannath, G. Tricot, 1996, Leukemia & lymphoma.

Engraftment syndrome after hematopoietic stem cell transplantation in multiple myeloma.

S. Jagannath, D. Vesole, A. Mazumder, 2006, Clinical Lymphoma & Myeloma.

Modern Trends in Autologous Bone Marrow Transplantation

S. Jagannath, J. Spinolo, F. Dunphy, 1989 .

Second bone marrow transplants for relapsed leukemia

S. Jagannath, J. Yau, G. Spitzer, 1992, Cancer.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip

B. Barlogie, M. Dimopoulos, H. Einsele, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies

S. Jagannath, D. Madduri, J. Jhang, 2018, Front. Immunol..

Blood Transfusion Management and Transfusion‐Related Outcomes in Daratumumab‐Treated Patients With Relapsed or Refractory Multiple Myeloma

S. Jagannath, A. Chari, S. Usmani, 2018, Clinical lymphoma, myeloma & leukemia.

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2021, Blood.

Leukemic cell colony formation in soft agar by bone marrow cells and peripheral blood cells from untreated acute leukemia patients.

S. Jagannath, S. Tucker, M. Lilien, 1983, Experimental hematology.

Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors

B. Barlogie, B. Cheson, S. Jagannath, 1990 .

High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma.

B. Barlogie, B. Cheson, S. Jagannath, 1990, Blood.

Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.

B. Barlogie, B. Cheson, S. Jagannath, 1990, Blood.

Radiation Therapy for Secondary Cutaneous Plasmacytomas

S. Jagannath, R. Phelps, R. Bakst, 2013, Case reports in hematology.

Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy.

B. Barlogie, S. Jagannath, G. Tricot, 1995, Bone marrow transplantation.

Autotransplants in myeloma.

B. Barlogie, S. Jagannath, 1992, Bone marrow transplantation.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

S. Jagannath, S. Lonial, D. Siegel, 2013, Haematologica.

Biology and therapy of multiple myeloma in 1996.

B. Barlogie, S. Jagannath, N. Munshi, 1997, Seminars in hematology.

Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age

S. Jagannath, R. Kyle, J. Wingard, 2003, Bone Marrow Transplantation.

High‐dose chemotherapy and unpurged autologous bone marrow transplantation for acute leukemia in second or subsequent remission

S. Jagannath, J. Spinolo, E. Estey, 1990, Cancer.

Selinexor for the treatment of multiple myeloma

J. Shah, S. Jagannath, P. Richardson, 2020, Expert opinion on pharmacotherapy.

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers

G. Morgan, S. Jagannath, Y. Taur, 2020, Blood cancer discovery.

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers

G. Morgan, S. Jagannath, A. Lesokhin, 2020, medRxiv.

Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.

B. Barlogie, S. Jagannath, D. Siegel, 1997, Leukemia & lymphoma.

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

H. Einsele, S. Jagannath, A. Jakubowiak, 2022, Haematologica.

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

H. Goldschmidt, S. Jagannath, D. Siegel, 2021, Blood Cancer Journal.

First thalidomide clinical trial in multiple myeloma: a decade.

B. Barlogie, J. Shaughnessy, S. Jagannath, 2008, Blood.

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.

Faith Davies, Edie Weller, Kenneth Anderson, 2004, Mayo Clinic proceedings.

A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma

A. Laganà, S. Jagannath, W. Pierceall, 2020, Leukemia & lymphoma.

A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

S. Jagannath, S. Parekh, A. Chari, 2016 .

Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.

S. Jagannath, S. Lonial, Shaji K. Kumar, 2014, Clinical lymphoma, myeloma & leukemia.

Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort

S. Jagannath, W. Dalton, D. Sullivan, 2012 .

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

H. Goldschmidt, M. Dimopoulos, S. Jagannath, 2016, Leukemia & lymphoma.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

D. Esseltine, S. Jagannath, N. Munshi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meeting Highlights: From: 49th Annual Meeting of the American Society of Hematology; Atlanta, GA; December 8–11, 2007

B. Cheson, S. Jagannath, S. Cunningham, 2008 .

Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

S. Jagannath, N. Munshi, A. Chanan-Khan, 2006 .

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

S. Jagannath, S. Girish, A. Solinger, 2006 .

Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment

M. Dimopoulos, S. Jagannath, A. Chanan-Khan, 2012, Clinical Cancer Research.

Novel therapeutic agents for the management of multiple myeloma patients with renal impairment

M. Dimopoulos, S. Jagannath, J. Miguel, 2012 .

Safety and Efficacy of Bortezomib in Multiple Myeloma Patients with Renal Failure Requiring Dialysis.

S. Jagannath, S. Lonial, S. Singhal, 2005 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

M. Dimopoulos, H. Einsele, P. Sonneveld, 2011, Blood.

Heterogeneity of Second‐Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010–2016)

J. Hardin, S. Jagannath, S. Srinivasan, 2018, Clinical lymphoma, myeloma & leukemia.

Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations

S. Jagannath, M. Sussman, N. Shah, 2021, Clinical Drug Investigation.

The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement

S. Jagannath, R. Kyle, J. Zonder, 2008, Leukemia.

The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement

S. Jagannath, R. Kyle, S. Berven, 2008, Leukemia.

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

S. Jagannath, M. Dhodapkar, G. Yancopoulos, 2020, Blood.

A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

S. Jagannath, S. Lonial, R. Kurzrock, 2013, Clinical Cancer Research.

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

S. Jagannath, M. Merad, D. D. Del Valle, 2020, Journal of Hematology & Oncology.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

David E. Irwin, S. Jagannath, S. Singhal, 2009, Blood.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Plasmacytoma in the breast with axillary lymph node involvement: a case report.

S. Jagannath, D. Axelrod, A. Mazumder, 2006, Clinical breast cancer.

Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data.

S. Jagannath, S. Tucker, W. Velasquez, 1989, Blood.

Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma

B. Barlogie, S. Jagannath, G. Tricot, 1997, Bone Marrow Transplantation.

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

S. Jagannath, N. Munshi, M. Liedtke, 2017 .

High-dose melphalan and total body irradiation with bone marrow transplantation for refractory malignancies.

S. Jagannath, A. Zander, W. Velasquez, 1986, European journal of cancer & clinical oncology.

Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy.

S. Jagannath, S. Tucker, W. Velasquez, 1991, Blood.

bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.

S. Jagannath, D. Siegel, N. Munshi, 2018 .

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

S. Jagannath, S. Lonial, D. Siegel, 2020 .

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

S. Jagannath, D. Siegel, N. Munshi, 2019, Blood.

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

S. Jagannath, A. Jakubowiak, J. Goldberg, 2019, Blood.

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

S. Jagannath, G. Yancopoulos, I. Lowy, 2019, Blood.

Role of NK Cells in Tumor Cell Growth and Eradication

S. Jagannath, E. Lotzová, C. Savary, 1989 .

Cellular immune responses against CT 7 ( MAGE-C 1 ) and humoral responses against other cancer-testis antigens in multiple myeloma patients

S. Jagannath, S. Chen‐Kiang, L. Old, 2005 .

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

A. Laganà, S. Jagannath, C. Schaniel, 2022, Blood.

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis

H. Einsele, S. Jagannath, D. Siegel, 2020, Transplantation and Cellular Therapy.

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, D. Siegel, 2021, Blood.

KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.

H. Goldschmidt, S. Jagannath, D. Siegel, 2020 .

Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, J. Goldberg, 2020 .

A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma

A. Laganà, S. Jagannath, D. Madduri, 2022, medRxiv.

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

J. Shah, M. Dimopoulos, S. Jagannath, 2021, American journal of hematology.

Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies.

B. Barlogie, S. Jagannath, D. Madduri, 2020, Clinical lymphoma, myeloma & leukemia.

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

J. Hardin, S. Jagannath, S. Srinivasan, 2018, Annals of Hematology.

Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.

J. Hardin, S. Jagannath, S. Srinivasan, 2018, Clinical therapeutics.

A case report of chronic myelogenous leukemia in a patient with multiple myeloma and a review of the literature.

S. Jagannath, V. Najfeld, J. Mascarenhas, 2013, Clinical lymphoma, myeloma & leukemia.

49th Annual Meeting of the American Society of Hematology, Atlanta, GA; December 8-11, 2007.

S. Jagannath, S. Cunningham, S. Muneer, 2008, Clinical lymphoma & myeloma.

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma

Kenneth C. Anderson, Joi Dunbar, S. Jagannath, 2011, Leukemia & lymphoma.

High-dose chemotherapy intensification with bone marrow support for hormone receptor negative or hormonal refractory relapsing breast cancer

G. Hortobagyi, S. Jagannath, A. Buzdar, 1989 .

Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.

S. Jagannath, W. Velasquez, P. Mclaughlin, 1988, Seminars in hematology.

Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).

S. Jagannath, A. Krishnan, M. Vogel, 2021 .

Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.

S. Jagannath, J. Spinolo, G. Zagars, 1990, Bone marrow transplantation.

Current standards for first-line therapy of multiple myeloma.

S. Jagannath, 2007, Clinical lymphoma & myeloma.

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis

R. Fonseca, S. Jagannath, M. Liedtke, 2021, Blood cancer journal.

Where you live can impact your cancer risk: a look at multiple myeloma in New York City.

Geetanjali R. Kamath, S. Jagannath, S. Parekh, 2020, Annals of epidemiology.

Introduction: addressing challenges in multiple myeloma management in an era of new therapeutics.

S. Jagannath, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

F. Zhan, S. Jagannath, A. Jakubowiak, 2011, European journal of haematology.

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.

S. Jagannath, S. Lonial, T. Zimmerman, 2019, Clinical lymphoma, myeloma & leukemia.

Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib

S. Jagannath, S. Lonial, D. Siegel, 2014 .

An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, British journal of haematology.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Phase 2 study of two sequential three‐drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

S. Jagannath, D. Vesole, B. Durie, 2010, British journal of haematology.

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

S. Jagannath, D. Schenkein, J. Lutzky, 2005, British journal of haematology.

Hemopoietic stem cell transplants for multiple myeloma.

B. Barlogie, S. Jagannath, G. Tricot, 1994, Oncology.

Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.

S. Jagannath, N. Munshi, P. Richardson, 2006 .

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

S. Jagannath, A. Krishnan, S. Lonial, 2018, Cancer.

Piperazinedione, total body irradiation, and autologous bone marrow transplantation in chronic myelogenous leukemia.

S. Jagannath, A. Zander, H. Kantarjian, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High‐Dose Cyclophosphamide, BCNU, and Etoposide Followed by Autologous Bone Marrow Rescue as Treatment for Adult Acute Leukemia in Relapse

S. Jagannath, A. Zander, M. Keating, 1986, American journal of clinical oncology.

Multiple Myeloma and Other Plasma Cell Dyscrasias

S. Jagannath, N. Munshi, P. Richardson, 2016 .

Stage IV diffuse large-cell lymphoma: a long-term analysis.

S. Jagannath, S. Tucker, W. Velasquez, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma.

S. Jagannath, D. Madduri, S. Parekh, 2021, Clinical lymphoma, myeloma & leukemia.

Thalidomide and lenalidomide in multiple myeloma.

S. Jagannath, A. Mazumder, 2006, Best practice & research. Clinical haematology.

Treatment of myeloma in patients not eligible for transplantation

S. Jagannath, 2005, Current treatment options in oncology.

Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies.

S. Jagannath, A. Chari, N. Biran, 2013, Clinical advances in hematology & oncology : H&O.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

J. Rossi, S. Jagannath, A. Jakubowiak, 2011 .

Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study.

J. Rossi, S. Jagannath, A. Jakubowiak, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.

S. Jagannath, R. Vij, P. Hari, 2021, Clinical lymphoma, myeloma & leukemia.

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis

J. Hardin, S. Jagannath, A. Agarwal, 2020, Cancer.

J. Hardin, S. Jagannath, S. Srinivasan, 2016 .

Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.

J. Hardin, S. Jagannath, S. Srinivasan, 2017 .

Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance

S. Jagannath, D. Madduri, S. Parekh, 2019, Blood.

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma

J. Rossi, P. Sonneveld, S. Jagannath, 2007 .

Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).

S. Jagannath, D. Siegel, R. Vij, 2012 .

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010 .

An inflammatory cytokine signature predicts COVID-19 severity and survival

S. Jagannath, C. Cordon-Cardo, M. Merad, 2020, Nature Medicine.

Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

S. Jagannath, A. Jakubowiak, D. Siegel, 2014 .

Interim Analysis Of The Mmrf Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles

Winnie S. Liang, J. Carpten, S. Jewell, 2013 .

A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma

A. Laganà, S. Jagannath, Manishkumar Patel, 2015 .

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy

S. Jagannath, S. Richard, 2022, BioDrugs.

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial

S. Jagannath, S. Lonial, P. Richardson, 2021, Blood.

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

A. Laganà, S. Jagannath, W. Pierceall, 2021, Blood.

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

P. Sonneveld, S. Jagannath, S. Lonial, 2020 .

for Previously Untreated Multiple Myeloma Superiority of Tandem Autologous Transplantation Over Standard Therapy

B. Barlogie, B. Cheson, S. Jagannath, 2013 .

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

S. Jagannath, C. Cordon-Cardo, S. Almo, 2022, Cancer Cell.

UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

S. Jagannath, A. Jakubowiak, P. Hari, 2021, Hematology, Transfusion and Cell Therapy.

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Y. Houvras, S. Jagannath, J. Dey, 2022, Blood.

MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma.

Y. Houvras, S. Jagannath, M. Dhodapkar, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.

S. Jagannath, D. Madduri, L. Pacaud, 2022, Clinical lymphoma, myeloma & leukemia.

A phase 1 study of lucatumumab, a fully human anti‐CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

S. Jagannath, B. Ewald, R. Maziarz, 2012, British journal of haematology.

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

S. Jagannath, A. Krishnan, M. Mehra, 2021, EJHaem.

Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop.

S. Jagannath, M. Dhodapkar, N. Raje, 2023, Clinical lymphoma, myeloma & leukemia.

Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

S. Jagannath, M. Dhodapkar, A. Boyapati, 2021, Blood.

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

S. Jagannath, D. Siegel, P. Hari, 2021, Blood.

Do Patients With Multiple Myeloma Enrolled in Clinical Trials Live Longer?

Geetanjali R. Kamath, S. Jagannath, N. Bickell, 2021, American journal of clinical oncology.

Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.

S. Jagannath, D. Vesole, A. Mazumder, 2010, Clinical lymphoma, myeloma & leukemia.

A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma.

S. Jagannath, N. Munshi, P. Richardson, 2005 .

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

S. Jagannath, N. Munshi, A. Chanan-Khan, 2009 .

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

S. Jagannath, A. Jakubowiak, J. Goldberg, 2019, Blood.

Problem of Tuberculosis Among Children in the Community : Situation Analysis in the Perspective Of Tuberculosis in India

S. Jagannath, V. Chadha, R. Arora, 1999 .

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

S. Jagannath, A. Jakubowiak, D. Siegel, 2020 .

Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma.

S. Jagannath, M. Bhandari, 2007, Clinical lymphoma & myeloma.

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, P. Hari, 2020, Transplantation and Cellular Therapy.

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

S. Jagannath, D. Siegel, N. Munshi, 2020 .

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2020 .

S. Jagannath, A. Jakubowiak, P. Hari, 2020, Transplantation and Cellular Therapy.

What Affects Treatment Underuse in Multiple Myeloma in the United States: A Qualitative Study

S. Jagannath, N. Bickell, Jenny J. Lin, 2023, Cancers.

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.

S. Jagannath, S. Lonial, D. Siegel, 2021, The Lancet. Haematology.

cells by lenalidomide: therapeutic implications Enhancement of ligand-dependent activation of human natural killer T

S. Jagannath, M. Dhodapkar, S. Nimer, 2010 .

Purging of T-lymphocytes with magnetic affinity colloid.

S. Jagannath, J. Yau, K. Dicke, 1990, Experimental hematology.

Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia.

S. Jagannath, A. Zander, H. Kantarjian, 1989, Bone marrow transplantation.

PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update.

S. Jagannath, D. Siegel, R. Vij, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg FISH) Enhances the Quantitative Detection of Chromosome Abnormalities In Plasma Cell Neoplasms Compared to Conventional FISH

S. Jagannath, Hai-Su Yang, T. Scholl, 2010 .

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

S. Jagannath, S. Lonial, D. Siegel, 2013 .

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

S. Jagannath, S. Lonial, T. Zimmerman, 2012 .

Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

S. Jagannath, N. Munshi, A. Agarwal, 2021, Blood.

Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis

S. Jagannath, A. Jakubowiak, P. Hari, 2021, Blood.

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.

S. Jagannath, S. Lonial, D. Siegel, 2021 .

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

H. Goldschmidt, S. Jagannath, S. Lonial, 2020 .

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

P. Sonneveld, S. Jagannath, S. Lonial, 2019, Blood.

Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).

M. Dimopoulos, K. Anderson, S. Jagannath, 2010 .

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.

A. Laganà, S. Jagannath, S. Parekh, 2017, Blood advances.

Bortezomib Therapy Alone and in Combination with Dexamethasone for Patients with Previously Untreated Multiple Myeloma.

S. Jagannath, D. Schenkein, J. Lutzky, 2005 .

A242 Vorinostat and Bortezomib in Relapsed/Refractory MM

S. Jagannath, D. Siegel, V. Richon, 2009 .

Treatment of Multiple Myeloma with Vorinostat in Combination with Bortezomib: A Case Series

S. Jagannath, D. Vesole, A. Mazumder, 2008 .

Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.

S. Jagannath, A. Jakubowiak, S. Lonial, 2013 .

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

S. Jagannath, Hui-Yi Lin, D. Sullivan, 2014 .

State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings.

S. Jagannath, L. Kostakoglu, A. Chari, 2014, European journal of radiology.

Digital Health for Patients With Multiple Myeloma: An Unmet Need.

S. Jagannath, N. Raje, O. Nadeem, 2021, JCO clinical cancer informatics.

J. Dudley, A. Laganà, J. Keats, 2020, bioRxiv.

Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study

Winnie S. Liang, J. Carpten, S. Jewell, 2021, medRxiv.

Recent Advances in the Understanding and Treatment of Multiple Myeloma

S. Jagannath, R. Schwartz, M. Vozniak, 2008, Journal of Managed Care Pharmacy : JMCP.

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma

S. Jagannath, M. Albitar, D. Berman, 2010, British journal of haematology.

A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma

S. Jagannath, S. Parekh, A. Chari, 2013 .

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma

S. Jagannath, A. Cohen, S. Valluri, 2023, Oncology and Therapy.

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

S. Jagannath, A. Jakubowiak, P. Hari, 2021 .

Double intensification with amsacrine/high dose ara-C and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia.

S. Jagannath, A. Zander, J. Spinolo, 1990, Bone marrow transplantation.

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

S. Jagannath, S. Lonial, T. Zimmerman, 2011 .

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

S. Jagannath, A. Jakubowiak, S. Lonial, 2012 .

A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,

P. Sonneveld, S. Jagannath, A. Krishnan, 2011 .

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

J. Rossi, S. Jagannath, A. Jakubowiak, 2010 .

Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study

S. Jagannath, S. Lonial, R. Vij, 2010 .

A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.

S. Jagannath, A. Krishnan, P. Hari, 2020 .

Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.

M. Kaminski, K. Griffith, S. Jagannath, 2013 .

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.

H. Goldschmidt, G. Morgan, P. Sonneveld, 2009 .

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

S. Jagannath, A. Jakubowiak, R. Vij, 2009 .

Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study

J. Shah, A. Palumbo, S. Jagannath, 2016 .

Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma

S. Jagannath, S. Lonial, D. Siegel, 2016 .

Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

S. Jagannath, S. Lonial, D. Siegel, 2012 .

Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

Michael L. Wang, S. Jagannath, D. Siegel, 2008 .

Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

S. Jagannath, A. Jakubowiak, D. Siegel, 2008 .

Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study

S. Jagannath, S. Lonial, P. Hari, 2012 .

Selinexor for the treatment of patients with previously treated multiple myeloma

S. Jagannath, S. Lonial, P. Richardson, 2021, Expert review of hematology.

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

J. Shah, M. Dimopoulos, C. Hofmeister, 2020, Leukemia.

OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa

H. Goldschmidt, H. Einsele, S. Jagannath, 2021, Clinical Lymphoma Myeloma and Leukemia.

Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial

K. Griffith, S. Jagannath, A. Jakubowiak, 2010 .

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2011 .

ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)

S. Jagannath, S. Lonial, P. Richardson, 2013 .

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

S. Jagannath, S. Lonial, R. Vij, 2009 .

Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma

S. Jagannath, N. Munshi, A. Chanan-Khan, 2008 .

Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myeloma.

B. Barlogie, S. Jagannath, G. Tricot, 1994, Journal of hematotherapy.

Dupilumab in Multiple Myeloma: A Case Series.

S. Jagannath, S. Parekh, D. Dubin, 2022, Clinical lymphoma, myeloma & leukemia.

Trial designs and endpoints for immune therapies in multiple myeloma

S. Jagannath, S. Parekh, E. Moshier, 2022, American journal of hematology.

Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

A. Laganà, S. Jagannath, P. Poulikakos, 2022, Journal of Hematology & Oncology.

Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

S. Jagannath, N. Munshi, A. Chanan-Khan, 2007 .

Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

A. Laganà, S. Jagannath, P. Poulikakos, 2023, Journal of Hematology & Oncology.

A Phase 2 Study of Bortezomib as First Line Therapy In Patients with Multiple Myeloma

S. Jagannath, D. Schenkein, J. Lutzky, 2004 .

Overall Survival Trends and Clinical Characteristics of Plasmacytoma in the United States: A National Cancer Database Analysis.

S. Jagannath, E. Moshier, K. Dharmarajan, 2019, Clinical lymphoma, myeloma & leukemia.

Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study.

S. Jagannath, P. Richardson, M. Albitar, 2009 .

Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.

M. Dimopoulos, S. Jagannath, S. Lonial, 2009 .

Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.

S. Jagannath, A. Chari, J. Mikhael, 2022, Clinical lymphoma, myeloma & leukemia.

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

S. Jagannath, P. Richardson, R. Benjamin, 2021, Blood.

Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

M. Dimopoulos, S. Jagannath, Xiwen Ma, 2021, American journal of hematology.

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Lee-Jen Wei, M. Dimopoulos, S. Jagannath, 2020, EJHaem.

Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

S. Jagannath, S. Lonial, D. Siegel, 2020, American journal of hematology.

Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

S. Jagannath, S. Parekh, A. Chari, 2021, Blood.

Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

S. Jagannath, S. Lonial, P. Richardson, 2015 .

Cytokine-mobilized peripheral blood CD34+Thy-1+Lin- human hematopoietic stem cells as target cells for transplantation-based gene therapy.

B. Barlogie, S. Jagannath, G. Tricot, 1995, Leukemia.

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy

S. Jagannath, S. Richard, 2022, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

S. Jagannath, S. Lonial, D. Siegel, 2019, Blood.

Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.

C. Hofmeister, S. Jagannath, S. Lonial, 2013 .

Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma.

S. Jagannath, E. Bagiella, A. Chari, 2015, Clinical lymphoma, myeloma & leukemia.

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

S. Jagannath, R. Vij, J. Kaufman, 2014 .

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

Linda Z Sun, H. Goldschmidt, M. Dimopoulos, 2011 .

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry

H. Goldschmidt, S. Jagannath, P. Hari, 2021, Cancers.

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

S. Jagannath, A. Krishnan, M. Vogel, 2021, Clinical Drug Investigation.

P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, S. Jagannath, S. Lonial, 2021, Clinical Lymphoma, Myeloma & Leukemia.

Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

S. Jagannath, S. Lonial, P. Richardson, 2014 .

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

S. Jagannath, M. Hildebrandt, R. Orlowski, 2019, Blood.

Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.

D. Esseltine, K. Anderson, S. Jagannath, 2010 .

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

S. Jagannath, A. Krishnan, P. Hari, 2019, Blood.

Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients

S. Jagannath, C. Cordon-Cardo, M. Merad, 2021, medRxiv.

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

J. Hardin, S. Jagannath, S. Srinivasan, 2017 .

Treatment Patterns From 2009-2015 in Patients With Newly Diagnosed Multiple Myeloma in the United States: A Report From the Connect® MM Registry

J. Hardin, S. Jagannath, S. Srinivasan, 2017 .

Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect® MM Registry

J. Hardin, S. Jagannath, S. Srinivasan, 2016 .

Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.

S. Jagannath, P. Richardson, K. Colson, 2006, Clinical advances in hematology & oncology : H&O.

A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.

Jason J. Z. Liao, S. Jagannath, S. Lonial, 2018 .

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

M. Dimopoulos, S. Jagannath, R. Vij, 2018, Blood.

A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.

Jason J. Z. Liao, H. Goldschmidt, S. Jagannath, 2018 .

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

S. Jagannath, S. Parekh, Kian Parsa, 2022, Blood.

Association between renal cell carcinoma and plasma cell dyscrasias: a case series of six patients.

S. Jagannath, D. Vesole, A. Mazumder, 2008, Clinical lymphoma & myeloma.

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis

C. Hofmeister, S. Jagannath, S. Lonial, 2012 .

Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).

Lee-Jen Wei, M. Dimopoulos, S. Jagannath, 2019, Journal of Clinical Oncology.

Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

S. Jagannath, S. Singhal, P. Richardson, 2008 .

Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma

S. Jagannath, P. Richardson, J. Zeldis, 2008 .

Effect of low‐dose granulocyte‐macrophage colony‐stimulating factor (LD‐GM‐CSF) on platelet transfusion‐dependent thrombocytopenia

B. Barlogie, S. Jagannath, D. Vesole, 1994, American journal of hematology.

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.

S. Jagannath, A. Jakubowiak, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry

J. Hardin, S. Jagannath, S. Srinivasan, 2020, British journal of haematology.

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

S. Jagannath, A. Jakubowiak, A. Lesokhin, 2023, Journal of Clinical Oncology.

LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.

Y. Houvras, S. Jagannath, M. Dhodapkar, 2023, Journal of Clinical Oncology.

Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study

H. Einsele, S. Jagannath, A. Jakubowiak, 2021, Blood.

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.

S. Jagannath, R. Vij, P. Hari, 2021 .

Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent and daratumumab.

S. Jagannath, M. Vogel, M. Mehra, 2020 .

KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

S. Jagannath, S. Lonial, N. Raje, 2021, Blood.

Interim Analysis of the MMRF CoMMpass Study: Comprehensive Characterization of Multiple Myeloma Patients at Diagnosis Reveals Distinct Molecular Subtypes and Clinical Outcomes

Winnie S. Liang, J. Carpten, J. Fay, 2015 .

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).

S. Jagannath, D. Siegel, S. Kanner, 2023, Journal of Clinical Oncology.

Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis

S. Jagannath, A. Chanan-Khan, T. Sher, 2010 .

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Blood.

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

M. Dimopoulos, S. Jagannath, P. Richardson, 2021, Blood.

Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone

M. Dimopoulos, S. Jagannath, Xiwen Ma, 2020 .

The role of thalidomide in multiple myeloma.

S. Jagannath, C. Schwab, 2006, Clinical Lymphoma & Myeloma.

Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma.

R. Fonseca, S. Jagannath, P. Richardson, 2007 .

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

B. Barlogie, S. Jagannath, S. Lonial, 2006 .

Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma

S. Jagannath, A. Palumbo, Emmanuelle Le Ray, 2016, Expert Review of Hematology.

Bortezomib in Combination with High-Dose Dexamethasone (HD dex) and Erythropoietin (EPO) Does Not Result in an Increased Risk of Thromboembolic Complications.

D. Esseltine, P. Sonneveld, S. Jagannath, 2006 .

A Phase I, Multi-Center, Dose Escalation Study of Atiprimod in Patients with Refractory or Relapsed Multiple Myeloma (MM).

Michael L. Wang, S. Jagannath, N. Munshi, 2005 .

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

H. Goldschmidt, A. Palumbo, H. Johnsen, 2014, The Lancet. Oncology.

Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma

S. Jagannath, A. Jakubowiak, Stephen Palmer, 2023, Oncology and Therapy.

Conflicts of interest, authorship, and disclosures in industry-related scientific publications.

B. Barlogie, J. Shaughnessy, R. Fonseca, 2010, Mayo Clinic proceedings.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

Phase III Trial: Bortezomib/Thalidomide/Dexamethasone Versus Thalidomide/Dexamethasone Alone: Efficacy

S. Jagannath, S. Lonial, S. Stilgenbauer, 2009 .

Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma.

S. Jagannath, H. Pri-Chen, A. Chari, 2013, Clinical lymphoma, myeloma & leukemia.

Appearance of Cytotoxic Cells within the Bronchus after Local Infection with Herpes Simplex Virus

S. Jagannath, R. Clancy, W. Rawls, 1977, The Journal of Immunology.

Enhancement of clonogenicity of human multiple myeloma by dendritic cells

S. Jagannath, M. Dhodapkar, D. Vesole, 2006, The Journal of experimental medicine.

Management of treatment-emergent peripheral neuropathy in multiple myeloma

P. Wen, G. Morgan, M. Dimopoulos, 2012, Leukemia.

Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma

J. Dudley, B. Barlogie, D. Auclair, 2018, Blood.

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis

S. Jagannath, M. Liedtke, S. Schönland, 2021, Blood Cancer Journal.

Interventions and outcomes of multiple myeloma patients receiving salvage treatment after BCMA-directed CAR T therapy.

S. Jagannath, A. Lesokhin, S. Parekh, 2022, Blood.

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma

A. Laganà, S. Jagannath, S. Parekh, 2022, Blood advances.

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.

S. Jagannath, A. Chanan-Khan, S. Ailawadhi, 2019, Clinical lymphoma, myeloma & leukemia.

Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions.

S. Jagannath, R. Desikan, 2001, Seminars in oncology.

The research mission in myeloma

S. Jagannath, A. Jakubowiak, N. Munshi, 2009, Leukemia.

First thalidomide clinical trial in multiple myeloma: a decade.

B. Barlogie, J. Shaughnessy, S. Jagannath, 2008, Blood.

Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect® MM Registry

J. Hardin, S. Jagannath, R. Rifkin, 2020, Blood.

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

S. Jagannath, S. Lonial, D. Siegel, 2013, Haematologica.

Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab

S. Jagannath, P. Voorhees, S. Parekh, 2015 .

Multiple myeloma, race, insurance and treatment.

S. Jagannath, M. Mazumdar, N. Bickell, 2021, Cancer epidemiology.

Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices

S. Jagannath, D. Globe, M. Eaddy, 2016, Expert review of hematology.

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

M. Kaminski, K. Griffith, S. Jagannath, 2012, Blood.

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure

C. Hofmeister, S. Jagannath, D. Siegel, 2012 .

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

M. Caligiuri, C. Hofmeister, S. Jagannath, 2015, Clinical Cancer Research.

Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies.

S. Jagannath, A. Chari, N. Biran, 2013, Clinical advances in hematology & oncology : H&O.

Progress in multiple myeloma.

S. Jagannath, 2008, Clinical lymphoma & myeloma.

Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma.

S. Jagannath, S. Parekh, A. Chari, 2016, Journal of Clinical Oncology.

KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).

S. Jagannath, J. Miguel, A. Palumbo, 2016 .

KEYNOTE-185: a randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM).

A. Palumbo, S. Jagannath, J. Miguel, 2016 .

Heterogeneity of Second‐Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010–2016)

J. Hardin, S. Jagannath, S. Srinivasan, 2018, Clinical lymphoma, myeloma & leukemia.

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study

J. Shah, M. Dimopoulos, S. Jagannath, 2019, Blood.